🧵 2/5 🧩 The Setup
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases. Director Jon Faiz Kayyem's half-million-dollar purchase adds a notable insider-conviction signal to an already volatile biotech story.
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases. Director Jon Faiz Kayyem's half-million-dollar purchase adds a notable insider-conviction signal to an already volatile biotech story.
The Insomniac Hedge Fund Guy
The Insomniac Hedge Fund Guy
buff.ly
September 28, 2026 at 10:07 PM
🧵 2/5 🧩 The Setup
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases. Director Jon Faiz Kayyem's half-million-dollar purchase adds a notable insider-conviction signal to an already volatile biotech story.
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases. Director Jon Faiz Kayyem's half-million-dollar purchase adds a notable insider-conviction signal to an already volatile biotech story.
📈 Insider Cluster Buy
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $1.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $1.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
September 28, 2026 at 9:55 PM
📈 Insider Cluster Buy
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $1.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
3 insiders at Inhibrx Biosciences, Inc. ($INBX) bought $1.5M in shares over 7 days.
https://earningsfeed.com/companies/2007919-inbx-inhibrx-biosciences-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_buy&utm_content=automated_signal
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study reut.rs/467CtVv
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a mid-stage study in patients with a type of head and neck cancer.
reut.rs
September 8, 2026 at 12:35 PM
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study reut.rs/467CtVv
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say reut.rs/4tVU2BA
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co , Germany’s Merck KGaA and Japan's Ono Pharmaceutical for an experimental cancer treatment that could be valued at more than $8 billion, people familiar with the matter said.
reut.rs
April 22, 2026 at 3:05 PM
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say reut.rs/4tVU2BA
For fifteen years, pharmaceutical giants like Pfizer , Genentech , GSK , and AstraZeneca attempted to activate the OX40 receptor of the immune system to attack tumors, and all failed.
Inhibrx achieves first victory in a 15-year immunotherapy target - Sinaptica
For fifteen years, pharmaceutical giants like Pfizer, Genentech, GSK, and AstraZeneca attempted to activate the OX40 receptor of the immune system to attack tum
sinapti.ca
September 8, 2026 at 12:17 PM
For fifteen years, pharmaceutical giants like Pfizer , Genentech , GSK , and AstraZeneca attempted to activate the OX40 receptor of the immune system to attack tumors, and all failed.
🧵 1/5 🧬 Inhibrx Biosciences Inc. ($INBX)—INSIDER BUY Alert
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00, for an estimated $500,000.
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00, for an estimated $500,000.
September 28, 2026 at 10:07 PM
🧵 1/5 🧬 Inhibrx Biosciences Inc. ($INBX)—INSIDER BUY Alert
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00, for an estimated $500,000.
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00, for an estimated $500,000.
2 insiders at Inhibrx Biosciences, Inc. just bought $INBX (top trade: $305K) One buy can be noise. 2 wallets reaching for the same stock in the same window — that's the filing I read twice.
September 29, 2026 at 2:00 PM
2 insiders at Inhibrx Biosciences, Inc. just bought $INBX (top trade: $305K) One buy can be noise. 2 wallets reaching for the same stock in the same window — that's the filing I read twice.
The CEO of Inhibrx Biosciences bought ~$450K of his own stock yesterday — in two separate purchases, same day, both discretionary. When a chief executive reaches for his wallet twice before lunch, that's a sentence in itself. ↓
September 29, 2026 at 12:06 PM
The CEO of Inhibrx Biosciences bought ~$450K of his own stock yesterday — in two separate purchases, same day, both discretionary. When a chief executive reaches for his wallet twice before lunch, that's a sentence in itself. ↓
SD Biotech M&A Tops $15B
Here's the largest acquisitions:
RayzeBio ($4.1B)
Longboard Pharma ($2.6B)
Inhibrx Bio ($2.2B)
Ambrx ($2B)
Poseida ($1.5B)
Escient Pharma ($750M)
Evofem Bio ($100M)
Despite a tough year for biotech...
Big pharma continues to expand into San Diego
Here's the largest acquisitions:
RayzeBio ($4.1B)
Longboard Pharma ($2.6B)
Inhibrx Bio ($2.2B)
Ambrx ($2B)
Poseida ($1.5B)
Escient Pharma ($750M)
Evofem Bio ($100M)
Despite a tough year for biotech...
Big pharma continues to expand into San Diego
December 10, 2024 at 6:10 PM
SD Biotech M&A Tops $15B
Here's the largest acquisitions:
RayzeBio ($4.1B)
Longboard Pharma ($2.6B)
Inhibrx Bio ($2.2B)
Ambrx ($2B)
Poseida ($1.5B)
Escient Pharma ($750M)
Evofem Bio ($100M)
Despite a tough year for biotech...
Big pharma continues to expand into San Diego
Here's the largest acquisitions:
RayzeBio ($4.1B)
Longboard Pharma ($2.6B)
Inhibrx Bio ($2.2B)
Ambrx ($2B)
Poseida ($1.5B)
Escient Pharma ($750M)
Evofem Bio ($100M)
Despite a tough year for biotech...
Big pharma continues to expand into San Diego
🚨 $INBX
On September 28, 2026, Inhibrx Biosciences, Inc. posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com.
On September 28, 2026, Inhibrx Biosciences, Inc. posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com.
SEC Filing: INBX
Click to view the official SEC document.
www.sec.gov
September 28, 2026 at 9:05 PM
🚨 $INBX
On September 28, 2026, Inhibrx Biosciences, Inc. posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com.
On September 28, 2026, Inhibrx Biosciences, Inc. posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com.
🔴 Inhibrx Biosciences has a Form 4 dated Sept. 28. The free headline stops there. No shares, price, insider, or transaction type—just a label pointing to a filing. The filing may disclose the trade; this article charges readers to find out what it was.
September 29, 2026 at 10:51 AM
🔴 Inhibrx Biosciences has a Form 4 dated Sept. 28. The free headline stops there. No shares, price, insider, or transaction type—just a label pointing to a filing. The filing may disclose the trade; this article charges readers to find out what it was.
Inhibrx and Oxford Finance Strengthen Partnership with Expanded Loan Agreement#USA#San_Diego#Clinical_Trials#Oxford_Finance#Inhibrx
Inhibrx and Oxford Finance Strengthen Partnership with Expanded Loan Agreement
Inhibrx Biosciences announces an expanded loan agreement with Oxford Finance, increasing funding to $500 million to advance clinical programs.
third-news.com
July 16, 2026 at 1:32 PM
Inhibrx and Oxford Finance Strengthen Partnership with Expanded Loan Agreement#USA#San_Diego#Clinical_Trials#Oxford_Finance#Inhibrx
Inhibrx's immunotherapy more than doubled responses versus Keytruda alone in HPV-driven head and neck cancer, and vaccine combos are next.
Inhibrx opens door to cancer vaccine combo for its OX40 agonist
Inhibrx says INBRX-106 plus Keytruda beats Keytruda alone in HNSCC data, with cancer-vaccine combination trials planned for early 2027.
endpoints.news
September 8, 2026 at 7:30 PM
Inhibrx's immunotherapy more than doubled responses versus Keytruda alone in HPV-driven head and neck cancer, and vaccine combos are next.
Inhibrx Biosciences Shares First Quarter 2026 Financial Updates#USA#San_Diego#Inhibrx_Biosciences#ozekibart#INBX-106
Inhibrx Biosciences Shares First Quarter 2026 Financial Updates
Inhibrx Biosciences has released its financial results for Q1 2026, detailing significant developments in their drug pipeline and fiscal performance.
third-news.com
May 14, 2026 at 8:06 PM
Inhibrx Biosciences Shares First Quarter 2026 Financial Updates#USA#San_Diego#Inhibrx_Biosciences#ozekibart#INBX-106
"Inhibrx claims first win for long-sought immunotherapy target"
#medsky #healthcare #hospice #healthpolicy #homehealth
#medsky #healthcare #hospice #healthpolicy #homehealth
Inhibrx claims first win for long-sought immunotherapy target
“Pushing this is like a rock up a hill, because there’s been so much failure in the space,” said Inhibrx CEO Mark Lappe.
www.statnews.com
September 8, 2026 at 12:00 PM
"Inhibrx claims first win for long-sought immunotherapy target"
#medsky #healthcare #hospice #healthpolicy #homehealth
#medsky #healthcare #hospice #healthpolicy #homehealth
$INBX: Jon Kayyem dropped $500K on Inhibrx, a biotech. Half a million of his own money on a drug developer — that's either conviction or a very expensive habit. His three past buys averaged +6.4%. One caveat: someone filed paperwork to sell soon.
September 25, 2026 at 12:06 PM
$INBX: Jon Kayyem dropped $500K on Inhibrx, a biotech. Half a million of his own money on a drug developer — that's either conviction or a very expensive habit. His three past buys averaged +6.4%. One caveat: someone filed paperwork to sell soon.
🧵 1/5 🧬 Inhibrx Biosciences Inc. ($INBX)—INSIDER BUY Alert
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00 (~$0.50M).
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00 (~$0.50M).
September 23, 2026 at 10:07 PM
🧵 1/5 🧬 Inhibrx Biosciences Inc. ($INBX)—INSIDER BUY Alert
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00 (~$0.50M).
Director Jon Faiz Kayyem bought 5,000 shares at an average price of $100.00 (~$0.50M).
Durante quince años, gigantes farmacéuticos como Pfizer , Genentech , GSK y AstraZeneca intentaron activar el receptor OX40 del sistema inmune para atacar tumores, y todos fracasaron.
Inhibrx logra la primera victoria en un objetivo de inmunoterapia buscado por 15 años - Sinaptica
Durante quince años, gigantes farmacéuticos como Pfizer, Genentech, GSK y AstraZeneca intentaron activar el receptor OX40 del sistema inmune para atacar tumores
sinapti.ca
September 8, 2026 at 12:17 PM
Durante quince años, gigantes farmacéuticos como Pfizer , Genentech , GSK y AstraZeneca intentaron activar el receptor OX40 del sistema inmune para atacar tumores, y todos fracasaron.
🧵 2/5 🧩 The Setup
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases, including cancer.
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases, including cancer.
The Insomniac Hedge Fund Guy
The Insomniac Hedge Fund Guy
buff.ly
September 23, 2026 at 10:07 PM
🧵 2/5 🧩 The Setup
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases, including cancer.
Inhibrx Biosciences is a clinical-stage biotechnology company developing biologic therapies for serious diseases, including cancer.
Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a mid-stage study in patients with a type of head and neck cancer.
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a mid-stage study in patients with a type of head and neck cancer.
reut.rs
September 8, 2026 at 12:30 PM
Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a mid-stage study in patients with a type of head and neck cancer.
@business: Sanofi will buy Inhibrx for as much as $2.2 billion, giving the French pharmaceutical firm ownership of a potential therapy for an inherited genetic condition called Alpha-1 Antitrypsin Deficiency https://t.co/rjiFbBJXA8
January 23, 2024 at 7:21 AM
@business: Sanofi will buy Inhibrx for as much as $2.2 billion, giving the French pharmaceutical firm ownership of a potential therapy for an inherited genetic condition called Alpha-1 Antitrypsin Deficiency https://t.co/rjiFbBJXA8
Inhibrx Founder & CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors? share.google/yIHSAM276Yqq...
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Motley Fool Press Release.
share.google
September 16, 2026 at 3:29 AM
Inhibrx Founder & CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors? share.google/yIHSAM276Yqq...